natgillin/translations-raw huggingface dataset:
Please refer to section 4.6 of the SPC for further details of adverse reactions.
Za več podrobnosti o neželenih učinkih glejte poglavje 4.6 Povzetka glavnih značilnosti zdravila.
Please refer to sections 4.4 and 4.5 for relevant interactions with antiretroviral agents.
Za podatke o medsebojnem delovanju s posameznimi protiretrovirusnimi zdravili glejte poglavji 4.4 in 4.5.
Please refer to the Aptivus Summary of Product Characteristics for additional information on the use of tipranavir, including genotypic predictors of response, in treatment of lopinavir-resistant HIV-1 infection.
Za dodatne informacije o tipranavirju (vključno z genotipsko napovedjo odziva, pri zdravljenju okužbe s HIV-1, odporne proti lopinavirju) glejte povzetek glavnih značilnosti zdravila Aptivus.
Please refer to the corresponding SmPC of medicinal products used in combination with ribavirin for further dosage recommendations on co-administration.
Za dodatna priporočila o odmerjanju pri sočasni uporabi, prosimo, glejte ustrezne povzetke glavnih značilnosti zdravil, uporabljenih v kombinaciji z ribavirinom.
Please refer to the corresponding SmPC of medicinal products used in combination with ribavirin.
Za nadaljnje informacije, prosimo glejte povzetek glavnih značilnosti teh zdravil (SmPC).
Please refer to the corresponding SmPC of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin and peginterferon alfa-2b.
Preberite si tudi ustrezne SmPC za protiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, da bi se bolj zavedali in bi lahko zdravili toksične učinke vsakega od teh zdravil ter da bi se zavedali potencialnega prekrivanja njihovih toksičnih učinkov z ribavirinom v kombinaciji s peginterferonom alfa- 2b.
Please refer to the corresponding SmPC of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin in combination with peginterferon alfa-2b.
Preberite si tudi ustrezne SmPC-je za protiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, da bi se bolj zavedali in bi lahko zdravili toksične učinke vsakega od teh zdravil ter da bi se zavedali potencialnega prekrivanja njihovih toksičnih učinkov z ribavirinom v kombinaciji s peginterferonom alfa- 2b.
Please refer to the corresponding Summary of Product Characteristics (SmPC) of medicinal products used in combination with ribavirin for additional prescribing information particular to that product and for further dosage recommendations on co-administration with ribavirin.
Za dodatne informacije glede predpisovanja in nadaljnjih priporočil glede odmerjanja pri sočasnejm zdravljenju z ribavirinom, prosimo, glejte posamezne povzetke glavnih značilnosti teh zdravil (SmPC- je).
Please refer to the dabrafenib SmPC.
Glejte povzetek glavnih značilnosti zdravila za dabrafenib.
Please refer to the doxorubicin SmPC for complete descriptions of all adverse events associated with doxorubicin treatment
Za popoln opis vseh neželenih učinkov, povezanih z zdravljenjem z doksorubicinom, glejte povzetek splošnih značilnosti zdravila za doksorubicin.
Please refer to the Kaletra 100 mg/25 mg film-coated tablets Summary of Product Characteristics.
Glejte povzetek glavnih značilnosti zdravila Kaletra 100 mg/25 mg filmsko obložene tablete.
Please refer to the Manufacturer’s Instructions for Use for cleaning and storage advice.
Za nasvete o čiščenju in shranjevanju glejte navodila izdelovalca za uporabo.
Please refer to the package leaflet of the medicine that is to be radiolabelled with Cuprymina.
Upoštevajte navodilo za uporabo zdravila, ki naj bi ga označili z radiofarmacevtskim predhodnikom Cuprymina.
Please refer to the package leaflet of the medicine that is to be radiolabelled with EndolucinBeta for additional information.
Za več informacij preberite navodilo za uporabo zdravila, ki bo radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta.
Please refer to the package leaflet of the medicine that is to be radiolabelled with EndolucinBeta for additional warnings and precautions.
Za dodatna opozorila in previdnostne ukrepe preberite navodilo za uporabo zdravila, ki bo radioaktivno označeno z radionuklidnim predhodnikom EndolucinBeta.
Please refer to the Package Leaflets of these other medicines for guidance on how to take them.
Glede napotkov za uporabo teh drugih zdravil glejte njihova navodila za uporabo.
Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.
Prosimo, preberite si navodila za uporabo tudi drugih protiretrovirusnih zdravil.
Please refer to the patient/carer reminder card attached to this leaflet.
Glejte opozorilno kartico za bolnika/skrbnika, ki je priložena temu navodilu.
Please refer to the product
Za navodila za prilagajanje
Please refer to the Ranexa SPC prior to prescribing any medications to this patient, as there are potential drug interactions which should be taken into consideration.
Preden temu bolniku predpišete katerokoli zdravilo, si preberite Povzetek glavnih značilnosti zdravila za zdravilo Ranexa, saj obstaja možnost, da bi lahko prišlo do medsebojnih delovanj z drugimi zdravili, ki bi jih bilo treba upoštevati.
Please refer to the respective SmPCs of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with PegIntron and ribavirin.
Prosimo, glejte ustrezne SmPC-je za antiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, za informacije o toksičnih učinkih in ustreznem ukrepanju za vsako zdravilo ter za informacije o potencialnem prekrivanju njihovih toksičnih učinkov z zdravilom PegIntron in ribavirinom.
Please refer to the respective SmPCs of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with PegIntron in combination with ribavirin.
Prosimo, glejte ustrezne SmPC za antiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, za informacije o toksičnih učinkih in ustreznem ukrepanju za vsako zdravilo ter za informacije o potencialnem prekrivanju njihovih toksičnih učinkov z zdravilom PegIntron in ribavirinom.
Please refer to the respective SmPCs of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ViraferonPeg in combination with ribavirin.
Prosimo, glejte ustrezne SmPC-je za antiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, za informacije o toksičnih učinkih in ustreznem ukrepanju za vsako zdravilo ter za informacije o potencialnem prekrivanju njihovih toksičnih učinkov z zdravilom ViraferonPeg in ribavirinom.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin and peginterferon alfa-2b.
Preberite si tudi ustrezne Povzetke glavnih značilnosti zdravila za protiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, da bi se bolj zavedali toksičnih učinkov vsakega od teh zdravil ter da bi se zavedali potencialnega prekrivanja njihovih toksičnih učinkov z ribavirinom v kombinaciji s peginterferonom alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin BioPartners and peginterferon alfa-2b.
Preberite si tudi ustrezne Povzetke glavnih značilnosti zdravila za protiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, da bi se bolj zavedali toksičnih učinkov vsakega od teh zdravil ter da bi se zavedali potencialnega prekrivanja njihovih toksičnih učinkov z zdravilom Ribavirin BioPartners v kombinaciji s peginterferonom alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin in combination with peginterferon alfa-2b.
Preberite si tudi ustrezne Povzetke glavnih značilnosti zdravila za protiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, da bi se zavedali toksičnih učinke vsakega od teh zdravil ter da bi se zavedali potencialnega prekrivanja njihovih toksičnih učinkov z ribavirinom v kombinaciji s peginterferonom alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin Teva Pharma B.V in combination with peginterferon alfa-2b.
Preberite si tudi ustrezne Povzetke glavnih značilnosti zdravila za protiretrovirusna zdravila, ki jih bo bolnik jemal skupaj s terapijo za HCV, da bi se zavedali toksičnih učinke vsakega od teh zdravil ter da bi se zavedali potencialnega prekrivanja njihovih toksičnih učinkov z zdravilom Ribavirin Teva Pharma B.V. v kombinaciji s peginterferonom alfa-2b.
Please refer to the SmPC for full product information.
Za vse informacije o zdravilu glejte Povzetek glavnih značilnosti zdravila:
Please refer to the SmPC for the 30 mg, 45 mg and 75 mg capsules (section 6.6).
Prosimo, glejte SmPC za 30-mg, 45-mg in 75-mg kapsule (poglavje 6.6).
Please refer to the SmPC.
Glejte povzetek glavnih značilnosti zdravila.
Please refer to the SmPC.
Prosimo, glejte Povzetek glavnih značilnosti zdravila.
Please refer to the Summaries of Product Characteristics for Viread 123 mg and 163 mg film-coated tablets for the treatment of HIV-1 infected paediatric patients aged 6 to < 12 years weighing
Glejte povzetka glavnih značilnosti zdravila Viread 123 mg in 163 mg filmsko obložene tablete za zdravljenje pediatričnih bolnikov, okuženih s HIV-1, starih 6 do < 12 let, s telesno maso
Please refer to the Summaries of Product Characteristics for Viread 123 mg and 204 mg film-coated tablets for the treatment of HIV-1 infected paediatric patients aged 6 to < 12 years weighing
Glejte povzetka glavnih značilnosti zdravila Viread 123 mg in 204 mg filmsko obložene tablete za zdravljenje pediatričnih bolnikov, okuženih s HIV-1, starih 6 do < 12 let, s telesno maso
Please refer to the Summaries of Product Characteristics for Viread 163 mg and 204 mg film-coated tablets for the treatment of HIV-1 infected paediatric patients aged 6 to < 12 years weighing
Glejte povzetka glavnih značilnosti zdravila Viread 163 mg in 204 mg filmsko obložene tablete za zdravljenje pediatričnih bolnikov, okuženih s HIV-1, starih 6 do < 12 let, s telesno maso
Please refer to the Summaries of Product Characteristics for Viread 245 mg film-coated tablets and Viread 33 mg/g granules.
Glejte povzetek glavnih značilnosti zdravila za zdravilo Viread 245 mg filmsko obložene tablete in Viread 33 mg/g zrnca.
Please refer to the Summary of Product Characteristics for Emtriva 10 mg/ml oral solution.
Prosimo, upoštevajte povzetek glavnih značilnosti Emtriva 10 mg/ml peroralne raztopine.
Please refer to the Summary of Product Characteristics for melphalan for information on overdose of melphalan.
Podatke o prevelikem odmerjanju melfalana preberite v Povzetku glavnih značilnosti melfalana.
Please refer to the Summary of Product Characteristics for Vitekta 85 mg tablets.
Glejte povzetek glavnih značilnosti zdravila za zdravilo Vitekta 85 mg tablete.
Please refer to the trametinib SmPC for additional information.
Za več informacij glejte povzetek glavnih značilnosti zdravila za trametinib.
Please refer to the trametinib SmPC.
Glejte povzetek glavnih značilnosti zdravila za trametinib.
Please refer to trametinib SmPC for information on method of administration when given in combination with dabrafenib.
Za informacije o načinu uporabe trametiniba pri jemanju v kombinaciji z dabrafenibom glejte povzetek glavnih značilnosti zdravila za trametinib.
Please report to your doctor:
Obvestite svojega zdravnika o naslednjem:
Please return the bottle containing any left over suspension to your pharmacist.
Stekleničko z morebitno preostalo suspenzijo vrnite v lekarno.
Please see also section 2 of this leaflet about the risk of allergic reactions.
Glejte tudi poglavje 2 tega navodila o tveganju alergijskih reakcij.
Please see If you get a hypo on what a hypo is and how to treat it.
Za razlago in navodila za ukrepanje v primeru pojava hipe glejte odstavek V primeru pojava hipe.
Please see If you get a hypo on what a hypo is and how to treat it.
Za razlago in navodila za ukrepanje v primeru pojava hipe glejte podpoglavje V primeru pojava hipe.
Please see section 4 for the warning signs of low blood sugar.
Opozorilni znaki nizkega krvnega sladkorja so opisani v poglavju 4.
Please see section 4.2 for IL-2 dispensing instructions.
Glejte poglavje 4.2 za navodila za odmerjanje IL-2.
Please see section 4.2.
Glejte poglavje 4.2.
Please see section 5 for instructions on how to store Enbrel.
Glede shranjevanja zdravila Enbrel glejte poglavje 5.
Please see section ‘Other medicines and INCIVO’.
Glejte poglavje ‘Druga zdravila in zdravilo INCIVO’.
Please see the end of section 4 for important information about hypoglycaemia and hyperglycaemia and its treatment.
Za pomembne nadaljnje informacije o hipoglikemji in hiperglikemiji ter njunem zdravljenju glejte zadnji del poglavja 4.
Please see trametinib SmPC (see section 4.6) when used in combination with trametinib.
Pri uporabi v kombinaciji s trametinibom glejte povzetek glavnih značilnosti zdravila za trametinib (glejte poglavje 4.6).
Please see ‘Do not take CRIXIVAN’ and ‘Do not take either CRIXIVAN or ritonavir’ above under Section 2 for an important list of medicines that you must not combine with CRIXIVAN.
Prosimo, glejte podpoglavji 'Ne jemljite zdravila CRIXIVAN' in 'Ne jemljite niti zdravila CRIXIVAN niti ritonavirja' v poglavju 2 za pomemben seznam zdravil, ki jih ne smete kombinirati z zdravilom CRIXIVAN.
Please see ‘Warnings and precautions’ in Section 2 above.
Prosimo, glejte 'Opozorila in previdnostni ukrepi' v poglavju 2.
Please speak to your doctor about this before you go home after being injected with Foscan.
Prosimo, da se o tem pogovorite z zdravnikom, še preden greste domov po injiciranju zdravila Foscan.
Please speak to your doctor immediately if you take EXUBERA and resume smoking or have smoked in the last 6 months before starting to take EXUBERA.
Prosimo, da se nemudoma pogovorite s svojim zdravnikom, če jemljete zdravilo EXUBERA in ste spet začeli kaditi ali ste kadili v zadnjih 6 mesecih pred začetkom jemanja zdravila EXUBERA.
Please speak to your doctor, pharmacist, or nurse for more information.
Za več informacij se posvetujte s svojim zdravnikom, farmacevtom ali z medicinsko sestro.
Please speak with your doctor if you belong to one of these patient groups:
Posvetujte se z zdravnikom, če spadate v eno od naslednjih skupin bolnikov:
Please speak with your doctor if you have a history of liver disease.
S svojim zdravnikom se pogovorite, če ste kdaj imeli jetrno bolezen.
Please speak with your doctor, pharmacist, or nurse should you have any questions or concerns.
Če imate kakršnakoli vprašanja ali ste zaskrbljeni, se posvetujte z zdravnikom, s farmacevtom ali z medicinsko sestro.
Please speak with your doctor,pharmacist, or nurse should you have any questions or concerns.
Če imate kakršnakoli vprašanja ali ste zaskrbljeni, se posvetujte z zdravnikom, s farmacevtom ali z medicinsko sestro.
Please stick round barcode label
Nalepite okroglo nalepko s črtno kodo
Please take Siklos in the morning before breakfast, with a glass of water or a very small amount of food.
Zdravilo Siklos jemljite zjutraj pred zajtrkom s kozarcem vode ali z zelo majhno količino hrane.
Please take these amounts into consideration if you are on a controlled sodium diet.
Te vrednosti upoštevajte, če ste na dieti z omejeno količino natrija.
Please take this into account if you are on a controlled sodium diet.
To morajo upoštevati bolniki, ki so na dieti z nadzorovanim vnosom natrija.
Please talk to your doctor about this if you have concerns.
Če imate pomisleke, se posvetujte z zdravnikom.
Please talk to your doctor as soon as possible if you notice any changes in your skin.
Če opazite kakršne koli spremembe na koži, se morate čim prej posvetovati z zdravnikom.
Please talk to your doctor as soon as you notice that you forgot a dose.
Takoj ko opazite, da ste odmerek izpustili, se pogovorite z zdravnikom.
Please talk to your doctor if you experience muscle pain, numbness in your arms or legs, or any bowel or bladder problems as these may be caused by pressure on your spinal cord.
Povejte svojemu zdravniku, če imate mišične bolečine, otrplost rok ali nog ali težave s črevesjem ali mehurjem, saj jih morda povzroča pritisk na vašo hrbtenjačo.
Please talk to your doctor if you experience stomach ache which continues, nausea (feeling sick) or vomiting (being sick) that is new or becomes worse.
Pogovorite se s svojim zdravnikom, če se vam na novo pojavijo bolečine v trebuhu, ki ne prenehajo, navzea (slabost) ali bruhanje, ali če se slednji poslabšajo.
Please talk to your doctor if you experience stomach ache which continues, nausea, (feeling sick) or vomiting (being sick) that is new or becomes worse.
Pogovorite se s svojim zdravnikom, če se vam na novo pojavijo bolečine v trebuhu, ki ne prenehajo, navzea (slabost) ali bruhanje, ali če se slednji poslabšajo.
Please talk to your doctor or nurse if you have any questions about the information in this card.
Če imate kakršna koli vprašanja o tej izkaznici, se posvetujte z zdravnikom ali medicinsko sestro.
Please talk to your doctor or pharmacist if you are taking any of the following medicines:
Če jemljete katerega koli od spodaj navedenih zdravil, se posvetujte z zdravnikom ali farmacevtom:
Please talk with your surgeon before the start of treatment if you have liver or kidney disease.
Če imate bolezen jeter ali ledvic, se pred začetkom zdravljenja pogovorite s svojim kirurgom.
Please tell your child’s doctor or pharmacist if your child is using or has recently used any other medicines, including medicines obtained without a prescription, dietary supplements and herbal medicines.
Obvestite otrokovega zdravnika ali farmacevta, če vaš otrok jemlje ali je pred kratkim jemal katerokoli zdravilo, tudi če ste ga dobili brez recepta, prehranska dopolnila in zeliščna zdravila.
Please tell your doctor about any of these things.
Zdravniku to povejte.
Please tell your doctor and dentist immediately if you experience any of these symptoms while being treated with XGEVA or after stopping treatment: pain in the mouth and/or jaw, swelling or non-healing of sores in the mouth or jaw, discharge, numbness or feeling of heaviness in the jaw, or loosening of a tooth could be signs of bone damage in the jaw (osteonecrosis).
Zdravniku in zobozdravniku morate takoj povedati, če se vam med zdravljenjem z zdravilom XGEVA ali po končanju vašega zdravljenja, pojavi kateri od naslednjih simptomov: bolečina v ustih in/ali čeljustnici, oteklost ali neceljenje razjed v ustih ali čeljustnici, izcedek, omrtvičenost ali občutek teže v čeljusti ali majanje zob so lahko znaki okvare kosti v čeljusti (osteonekroze).
Please tell your doctor before you are given Paxene if you: are taking ritonavir, nelfinavir, efavirenz, nevirapine (for the treatment of AIDS) or any other prescribed medicines for your condition;
Prosimo, da predno boste prejeli zdravilo Paxene, svojemu zdravniku poveste, če: jemljete ritonavir, nelfinavir, efavirenz, nevirapin (za zdravljenje AIDS-a) ali katerokoli drugo zdravilo, ki so vam ga predpisali za vašo bolezen;
Please tell your doctor if in the past 2 days you have:
Povejte svojemu zdravniku, če ste imeli v preteklih 2 dneh:
Please tell your doctor if this occurs.
O njih morate obvestiti zdravnika.
Please tell your doctor if you are breast- feeding or planning to breast-feed.
Če dojite ali načrtujete dojenje, se o tem posvetujte s svojim zdravnikom.
Please tell your doctor if you are suffering or have suffered from:
Zdravniku povejte, če imate ali ste kdaj imeli:
Please tell your doctor if you are suffering or have suffered from:
Zdravniku povejte,če imate ali ste kdaj imeli:
Please tell your doctor if you are taking an oral contraceptive, as your doctor may recommend the addition of a non-hormonal contraceptive method.
Zdravnika morate obvestiti, če jemljete kakšen peroralen kontraceptiv (kontracepcijske tablete): zdravnik vam bo morda svetoval, da dodatno uporabljate še nek nehormonski način kontracepcije.
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen).
Obvestite zdravnika, če jemljete kakšna zdravila proti bolečinam ali vnetju (oteklinam), kot so zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAIDs), vključno z zdravili, ki ste jih dobili brez recepta (kot je ibuprofen).
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen).
Prosimo, povejte svojemu zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo ibuprofen).
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen).
Prosimo, povejte svojemu zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID-i), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen).
Prosimo, povejte svojemu zdravniku, če jemljete zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID-i), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen).
Prosimo, povejte zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID-i), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).
Please tell your doctor if you are taking any medicines for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen).
Prosimo, povejte svojemu zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID-i), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).